Back to Search
Start Over
IL-1 blockade with anakinra for severe inflammatory symptoms during chemotherapy for acute lymphoblastic leukemia
- Publication Year :
- 2022
-
Abstract
- Anakinra is a recombinant interleukin (IL)-1 receptor antagonistusedforseveralinflammatoryconditionsincludingsystemicjuvenileidiopathicarthritis,recurrentpericarditis,andfamilialMediterraneanfever (FMF). Its efficacy in blocking IL-1 and its manageable safetyprofilesupportitsusealsoinotherconditions,suchassepsis,acutemyocardialinfarction,andCOVID-19
- Subjects :
- Oncology
Anakinra
medicine.medical_specialty
Chemotherapy
business.industry
Il-1
Lymphoblastic Leukemia
medicine.medical_treatment
Hematology
acute lymphoblastic leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Blockade
Interleukin 1 Receptor Antagonist Protein
Internal medicine
Pediatrics, Perinatology and Child Health
Acute Disease
medicine
Humans
business
medicine.drug
Interleukin-1
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....c087e97ce33b132449c8eef455187c15
- Full Text :
- https://doi.org/10.1002/pbc.29404